Literature DB >> 19454424

Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up.

M Baccarani1, M Dreyling.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19454424     DOI： 10.1093/annonc/mdp143

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  Therapeutic drug monitoring and tyrosine kinase inhibitors.

Authors:  Pauline Herviou; Emilie Thivat; Damien Richard; Lucie Roche; Joyce Dohou; Mélanie Pouget; Alain Eschalier; Xavier Durando; Nicolas Authier
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

Review 2.  Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Authors:  Paul L McCormack; Susan J Keam
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

3.  Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese patients with a high-risk of gastrointestinal stromal tumor recurrence.

Authors:  Yuki Ushimaru; Tsuyoshi Takahashi; Kiyokazu Nakajima; Ryugo Teranishi; Toshirou Nishida; Seiichi Hirota; Masaaki Motoori; Takeshi Omori; Ryohei Kawabata; Kazuhiro Nishikawa; Takuro Saito; Kotaro Yamashita; Koji Tanaka; Tomoki Makino; Kazuyoshi Yamamoto; Yukinori Kurokawa; Hidetoshi Eguchi; Yuichiro Doki
Journal:  Int J Clin Oncol       Date:  2022-02-12       Impact factor: 3.402

4.  Management of imatinib-resistant patients with chronic myeloid leukemia.

Authors:  Pavan Kumar Bhamidipati; Hagop Kantarjian; Jorge Cortes; A Megan Cornelison; Elias Jabbour
Journal:  Ther Adv Hematol       Date:  2013-04

5.  Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.

Authors:  Carmino Antonio de Souza; Katia Borgia Barbosa Pagnano; Israel Bendit; Monika Conchon; Carla Maria Boquimpani de Moura Freitas; Arthur Moellmann Coelho; Vaneuza Araújo Moreira Funke; Wanderley Marques Bernardo
Journal:  Rev Bras Hematol Hemoter       Date:  2012

6.  Nilotinib: in the first-line treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

Review 7.  Suboptimal responses in chronic myeloid leukemia: implications and management strategies.

Authors:  Elias Jabbour; Giuseppe Saglio; Timothy P Hughes; Hagop Kantarjian
Journal:  Cancer       Date:  2011-10-28       Impact factor: 6.860

8.  Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.

Authors:  Wiltrud Haaß; Helga Kleiner; Christel Weiß; Claudia Haferlach; Brigitte Schlegelberger; Martin C Müller; Rüdiger Hehlmann; Wolf-Karsten Hofmann; Alice Fabarius; Wolfgang Seifarth
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

9.  Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1.

Authors:  Yao-Hua Lu; Zhong-Yi Huang
Journal:  Mol Med       Date:  2021-11-15       Impact factor: 6.354
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.